Tag:

Merck KgAA

Latest Headlines

Latest Headlines

Ambitious cancer R&D plans may explain Merck KGaA cutbacks

Anyone looking for some perspective on Merck KGaA's recent R&D cutbacks should check out an interview CFO Marcus Kuhnert gave to CNBC. 

Ablynx gets caught in Merck KGaA's R&D retreat

A fast-changing Merck KGaA is backing away from discovery and preclinical R&D deals it set up with the antibody specialists at Ablynx. And the Belgian biotech saw its shares slide 14% today after news of the prospective breakup--included in Ablynx's annual summary--spread in the markets.

After painful odyssey, Newron wins European OK for Parkinson's add-on

More than three years after Merck KGaA decided to dump its partnership with Milan-based Newron Pharmaceuticals, which in turn iced a planned buyout by Biotie, the Italian biotech has persevered to win European approval to market safinamide as an add-on drug for Parkinson's disease.

UPDATED: Merck KGaA carves into MS R&D after a string of setbacks

After seeing its reputation as a leader in multiple sclerosis erode over recent years, Merck KGaA has decided to carve back the number of staffers working in preclinical R&D in the field.

Merck KGaA abandons Symphogen's cancer drug ahead of Phase III

Merck KGaA, in the process of paring down its pipeline, is walking away from a $625 million deal with Symphogen and handing back the company's lead asset, a targeted cancer treatment in midstage trials.

Pfizer powers into immuno-oncology with $2.85B R&D pact with Merck KGaA

Pfizer is determined to be a major player in the fast-emerging field of immuno-oncology, and the pharma giant is paying handsomely to buy its way into an anti-PD-L1 program now underway at Merck KGaA. In a deal announced Monday Pfizer outlined plans to pay a whopping $850 million upfront and up to $2 billion in milestones for the right to co-develop and co-market MSB0010718C and any other IO drugs they put in the pipeline.

Top 10 Phase III disasters of 2014

Welcome to the hall of shame, where blockbuster drug projections go to die. This list includes some drugs that clearly should never have wound up in Phase III to begin with, a few that were steered back to the clinic in a doomed attempt to mine something positive, and a couple of notable exceptions that may have helped advance the field by exploring the outer limits of new drug technology.

Merck KGaA bags Sigma-Aldrich's global lab services, manufacturing ops in $17B buyout

Merck KGaA has come up with its long-awaited buyout deal, acquiring the life sciences services outfit Sigma-Aldrich for $17 billion.

Struggling Merck KGaA plans blockbuster R&D campaign for biosimilars, pact for PD-L1

Fresh from writing off one of its top late-stage programs, Merck KGaA stepped up with a revised comeback plan today, detailing plans to invest about $500 million in a late-stage effort to develop new biosimilars while scouting for a major-league partner to come in on its PD-L1 immuno-oncology program. And the company pointed to its current lineup of three star players in the pipeline, including one that has already posted a clinical failure.

Sutro adds Merck KGaA to its roster of marquee 'armed antibody' partners

Sutro Biopharma has landed another marquee name for its list of development partners for antibody-drug conjugates. Merck KGaA, which has been struggling in the clinic for years, has signed on with the San Francisco-based biotech, offering a $300 million package of milestones along with some unspecified research support.